1805 – Concizumab for routine prophylaxis to prevent bleeding in patients with haemophilia B

Novo Nordisk Pharmaceuticals Pty. Limited

Referral from the National Blood Authority.

Concizumab is a humanised recombinant monoclonal antibody of the immunoglobulin G4 isotype for patients with haemophilia B. It is a once daily injection administered under the skin to help reduce the risk and/or severity of bleeding episodes experienced by people with haemophilia B. 

Type: Therapeutic

Haemophilia B (HMB) is a congenital lifelong bleeding disorder caused by deficiency or dysfunction of the coagulation protein factor IX (FIX). HMB patients experience spontaneous, painful bleeding episodes and prolonged, excessive haemorrhage following trauma or surgery. 

Provide your input online

The following consultation deadlines apply:

• Pre-PASC consultation deadline: Friday 11 July 2025 11:59pm AEDT
• Pre-MSAC consultation deadline: 

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: 15 August 2025
• ESC meeting: 
• MSAC meeting: 

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.